We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Strong Asceniv Sales Drive ADMA Biologics Further?
Read MoreHide Full Article
Key Takeaways
ADMA posted $114.8M in Q1 revenues, driven by record Asceniv sales.
The new process ups IG output by 20%, supporting ADMA's $500M revenue target for 2025.
Despite gains, ADMA trades at 7.68x sales and faces EPS estimate cuts amid stiff plasma therapy competition.
ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases.
ADMA’s lead product, Asceniv, is a plasma-derived Intravenous Immune Globulin that contains naturally occurring polyclonal antibodies. It is indicated for the treatment of primary immunodeficiency disease or inborn errors of immunity in adults and adolescents.
The company recorded revenues of $114.8 million in the first quarter, driven by record-high Asceniv sales.
The recent FDA approval of ADMA’s yield enhancement production process is expected to pave the way for solid revenue growth and margin expansion. This approval is expected to increase finished immunoglobulin (IG) output by 20%.
ADMA expects to generate revenues of more than $500 million in 2025 and $625 million in 2026.
An acceleration in new patient starts and further penetration in existing markets should significantly expand Asceniv's sales.
Asceniv’s robust intellectual property estate, encompassing proprietary plasma screening assays, unique plasma pooling methods and innovative IG use, secures brand protection through at least 2035, with potential IP extensions beyond 2035.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. Its main plasma products are IG, Factor VIII, Alpha 1 (A1PI) and albumin. Grifols also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX and plasma thromboplastin component.
GRFS has a strong presence in various segments of the plasma derivatives industry, including A1PI, IG and albumin. It also has dominance in plasma collection centers and fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard S/D. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881) and liquid low IgA IG (TAK-880). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have gained 7.3% year to date against the industry’s decline of 2.6%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 7.68x forward sales, higher than its mean of 3.33x and the industry’s 1.64x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2025 and 2026 earnings per share has moved southward in the past 60 days.
Image: Bigstock
Will Strong Asceniv Sales Drive ADMA Biologics Further?
Key Takeaways
ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases.
ADMA’s lead product, Asceniv, is a plasma-derived Intravenous Immune Globulin that contains naturally occurring polyclonal antibodies. It is indicated for the treatment of primary immunodeficiency disease or inborn errors of immunity in adults and adolescents.
The company recorded revenues of $114.8 million in the first quarter, driven by record-high Asceniv sales.
The recent FDA approval of ADMA’s yield enhancement production process is expected to pave the way for solid revenue growth and margin expansion. This approval is expected to increase finished immunoglobulin (IG) output by 20%.
ADMA expects to generate revenues of more than $500 million in 2025 and $625 million in 2026.
An acceleration in new patient starts and further penetration in existing markets should significantly expand Asceniv's sales.
Asceniv’s robust intellectual property estate, encompassing proprietary plasma screening assays, unique plasma pooling methods and innovative IG use, secures brand protection through at least 2035, with potential IP extensions beyond 2035.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. Its main plasma products are IG, Factor VIII, Alpha 1 (A1PI) and albumin. Grifols also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX and plasma thromboplastin component.
GRFS has a strong presence in various segments of the plasma derivatives industry, including A1PI, IG and albumin. It also has dominance in plasma collection centers and fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard S/D. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881) and liquid low IgA IG (TAK-880). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have gained 7.3% year to date against the industry’s decline of 2.6%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 7.68x forward sales, higher than its mean of 3.33x and the industry’s 1.64x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2025 and 2026 earnings per share has moved southward in the past 60 days.
Image Source: Zacks Investment Research
ADMA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.